GlassScriptPhysician profile
Angela Spears
NPI 1053956094
$1,338.35
in general payments reported to CMS, 2019-2025
15 companies · $1,122 in 2025
The $1,122 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.74 · 2023: $16.13 · 2024: $179 · 2025: $1,122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,317.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $312.72 | 2024-2025 | |
| Incyte Corporation | $276.35 | 2025 | Opzelura, Opzelura |
| Journey Medical Corporation | $146.91 | 2025 | |
| Kerecis Limited | $142.91 | 2024-2025 | Kerecis Surgiclose, Kerecis Graftguide, Kerecis Omega3 Marigen |
| Novartis Pharmaceuticals Corporation | $106.79 | 2025 | |
| Galderma Laboratories, L.P. | $69.16 | 2025 | Nemluvio |
| Amgen INC. | $66.69 | 2025 | Otezla |
| Lilly USA, LLC | $43.80 | 2025 | Ebglyss |
| Mayne Pharma Commercial LLC | $38.72 | 2025 | |
| Organogenesis INC. | $30.51 | 2025 | Affinity |
| Regeneron Healthcare Solutions, INC. | $28.06 | 2024 | Libtayo |
| Janssen Biotech, INC. | $23.63 | 2025 | Tremfya |
| Philips North America LLC | $20.74 | 2021 | |
| Pulmonx Corporation | $16.13 | 2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Pfizer INC. | $15.23 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Spears listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.